HIV-1 Vpr-chloramphenicol acetyltransferase fusion proteins: Sequence requirement for virion incorporation and analysis of antiviral effect

Gene Therapy

Volumn 6, Issue 9, 1999, Pages 1590-1599

  Yao, X J ^a   Kobinger, G P ^a   Dandache, S ^a   Rougeau, N ^a   Cohen, E A ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Antiviral effect; HIV 1; HIV 1 protease cleavage site; Virion incorporation; Vpr chloramphenicol acetyltransferase fusion protein

Indexed keywords

CHIMERIC PROTEIN; CHLORAMPHENICOL ACETYLTRANSFERASE; HYBRID PROTEIN; ISOLEUCINE; LEUCINE; PROTEINASE; VPR PROTEIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL CYCLE G2 PHASE; CELL GROWTH; HUMAN IMMUNODEFICIENCY VIRUS 1; MORPHOGENESIS; NONHUMAN; PRIORITY JOURNAL; VIRION; VIRUS INFECTIVITY; VIRUS PARTICLE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CHLORAMPHENICOL O-ACETYLTRANSFERASE; COS CELLS; GENE PRODUCTS, VPR; GENE THERAPY; GENE TRANSFER TECHNIQUES; HIV; HIV PROTEASE; HUMANS; MOLECULAR SEQUENCE DATA; RECOMBINANT FUSION PROTEINS; VIRUS INTEGRATION;

FELIS CATUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0032863222     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300988     Document Type: Article

References (41)

1. Cohen EA, Dehni G, Sodroski JG, Haseltine WA. Human immunodeficiency virus Vpr product is a virion-associated regulatory protein. J Virol 1990; 64: 3097-3099.
2. Yu X-F, Matsuda M, Essex M, Lee TH. Open reading frame Vpr of simian immunodeficiency virus encodes a virion-associated protein. J Virol 1990; 64: 5688-5693.
3. Heinzinger NK et al. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 1994; 91: 7311-7315.
4. Levy DN, Fernandes LS, Williams WV, Weiner DB. Induction of cell differentiation by human immunodeficiency virus 1 Vpr. Cell 1993; 72: 541-550.
5. Rogel ME, Wu LI, Emerman M. The human immunodeficiency virus type 1 Vpr gene prevents cell proliferation during chronic infection. J Virol 1995; 69: 882-888.
6. He J et al. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 1995; 69: 6705-6711.
7. Re F, Braaten D, Franke EK, Luban J. Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J Virol 1995; 69: 6859-6864.
8. Goh WC et al. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nature Med 1998; 4: 65-71.
9. Subbramanian RA et al. Human immunodeficiency virus type 1 is a positive regulator of viral transcription and infectivity in primary human macrophages. J Exp Med 1998; 187: 1103-1111.
10. Yao X-J et al. Vpr stimulates viral expression and induces cell killing in human immunodeficiency virus type 1 infected dividing Jurkat T cells. J Virol 1998; 72: 4686-4693.
11. Mahalingam S et al. Mutagenesis of the putative alpha-helical domain of the Vpr protein of human immunodeficiency virus type 1: effect on stability and virion incorporation. Proc Natl Acad Sci USA 1995; 92: 3794-3798.
12. Yao X-J et al. Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. J Virol 1995; 69: 7032-7044.
13. Paxton W, Connor RI, Landau NR. Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of Gag and mutational analysis. J Virol 1993; 67: 7229-7237.
14. Lu YL, Spearman P, Ratner L. Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions. J Virol 1993; 67: 6542-6550.
15. gag precursor for incorporation of the Vpr product into human immunodeficiency type 1 viral particles. J Virol 1994; 68: 1926-1934.
16. gag domain of human immunodeficiency type 1 is sufficient for the incorporation of Vpr into heterologous viral particles. J Virol 1995; 69: 6304-6313.
17. gag. J AIDS Hum Retrovirol 1995; 10: 1-7.
18. Lu YL et al. A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J Virol 1995; 69: 6873-6879.
19. Kondo E, Göttlinger HG. A conserved LXXLF sequence is the major determinant in p6gag required for the incorporation of human immunodeficiency virus type 1 Vpr. J Virol 1996; 70: 159-164.
20. Li M-S et al. The Vpr protein of human immunodeficiency virus type 1 binds to nucleocapsid protein p7 in vitro. Biochem Biophy Res Commun 1996; 218: 352-355.
21. de Rocquigny H et al. The zinc fingers of HIV nucleocapsid protein NCp7 direct interaction with the viral regulatory protein Vpr. J Biol Chem 1997; 273: 30753-30759.
22. Wu X-Y et al. Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. EMBO J. 1997; 16: 5113-5122.
23. Fletcher TM et al. Complementation of integrase function in HIV-1 virions. EMBO J 1997; 16: 5123-5138.
24. Sato A et al. Targeting of chloramphenicol acetyltransferase to human immunodeficiency virus particles via Vpr and Vpx. Microbiol Immunol 1995; 39: 1015-1019.
25. Park J-W, Sodroski J. Targeting a foreign protein into virion particles by fusion with the Vpx protein of simian immunodeficiency virus. J AIDS Hum Retrovirol 1995; 11: 341-350.
26. Wu X-Y et al. Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx. J Virol 1995; 69: 3389-3398.
27. Wu X-Y et al. Inhibition of human and simian immunodeficiency virus type protease function by targeting Vpx-protease-mutant fusion protein into viral particles. J Virol 1996; 70: 3378-3384.
28. Kobinger GP et al. Virion-targeted viral inactivation against the human immunodeficiency type 1 using Vpr fusion proteins. J Virol 1998; 72: 5441-5448.
29. Zhao LJ, Mukherjee S, Narayan O. Biochemical mechanism of HIV-1 Vpr function: specific interaction with a cellular protein. J Biol Chem 1994; 269: 15577-15582.
30. Di Marzio P et al. Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr. J Virol 1995; 69: 7909-7916.
31. Mahalingam S et al. Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr. J Virol 1997; 71: 6339-6347.
32. Göttlinger HG, Dorfman T, Sodroski JG, Haseltine WA. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci USA 1991; 88: 3195-3199.
33. Darke PL et al. HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochem Biophys Res Commun 1988; 156: 297-303.
34. Göttlinger HG, Sodroski JG, Haseltine WA. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of Human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1989; 86: 5781-5785.
35. Kimpton J, Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J Virol 1992; 66: 2232-2239.
36. Cohen EA et al. Identification of HIV-1 Vpr product and function. J Acquir Immun Def Synd 1990; 1: 11-18.
37. Serio D et al. Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication. Proc Natl Acad Sci USA 1997; 94: 3346-3351.
38. Coffin JM, Hughes SH, Varmus HE. Retroviruses. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1997, pp 27-69.
39. Henderson LE et al. Isolation and characterization of a novel protein (x-orf product) from SIV and HIV-2. Science 1988; 241: 199-201.
40. Matsuda Z et al. A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993; 90: 3544-3548.
41. Lee MH, Sano K, Morales FE, Imagawa DT. Sensitive reverse transcriptase assay to detect and quantitate human immunodeficiency virus. J Clin Microbiol 1987; 25: 1717-1721.